NCT05882734 2026-02-17
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
EMD Serono
Phase 1/2 Active not recruiting
EMD Serono
Palleon Pharmaceuticals, Inc.
OncoResponse, Inc.
Vanderbilt-Ingram Cancer Center
OncoResponse, Inc.
Sanofi